Notification of Policy Revisions Effective April 1, 2022 (Posted February 15, 2022)
Policy Name | Revised Criteria |
Injectable and Healthcare Administered Oncology Drugs “Notification” | Added newly approved Kimmtrak to policy for treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, and associated dosing to FDA label reference table. Addition of Erwinaze, Rybrevant, Rylaze, and Tivdak to remain on notice for effective date 4/1/2022. Additional policy notification given 2/15/2022 for effective date 4/1/2022. |